Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

NCT01741116 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG: TKI258

Sponsor

Korean Cancer Study Group